3 Reasons HAE is Risky and 1 Stock to Buy Instead
Affected assets and topics
Why it matters
Haemonetics's shares have declined 7.2% over the last six months, underperforming the S&P 500, which gained 6.1%. This underperformance may prompt investors to reconsider their investment in HAE. The article suggests considering an alternative stock investment.
- HAE's 7.2% decline over six months
- S&P 500's 6.1% gain over the same period
Expected market reaction
The decline in HAE's shares may lead to a sector-wide rotation, potentially affecting other healthcare stocks. In contrast, the S&P 500's gain may attract investors seeking broader market exposure, possibly at the expense of individual underperforming stocks like HAE.
Risks
- Further decline in HAE's shares if investors lose confidence
- Sector-wide rotation out of underperforming healthcare stocks
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.3-70b-versatile
- Analysis version
- groq-llama-3.3-70b-versatile
- Article id
- 102018
- Timeframe
- 24h
Prediction lifecycle
-
Llama 3.3 70B Versatile (Groq) HAE Bearish 60%Generated 6h 24h Excluded
Expired: not evaluated within 7 days of its 24h timeframe elapsing
Logged at publication, scored automatically once the window closes — never edited.
Original source
Over the last six months, Haemonetics’s shares have sunk to $75.12, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 6.1% gain. This might have investors contemplating their next move.
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on June 30, 2026. Analysis and insights provided by AnalystMarkets AI.
This model on similar stories
Insufficient sample · n=3 — Llama 3.3 70B Versatile (Groq) needs 30 scored calls on equities before an accuracy figure means anything.